QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.108.025726v1 37/4/695    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stresser, D. M. Articles by Dehal, S. S. Search for Related Content PubMed PubMed Citation Articles by Stresser, D. M. Articles by Dehal, S. S.

SHORT COMMUNICATION

Differential Time- and NADPH-Dependent Inhibition of CYP2C19 by Enantiomers of Fluoxetine

BD Biosciences, BD Gentest Contract Research Services, Woburn, Massachusetts

Fluoxetine [±-N-methyl-3-phenyl-3-[(, , (-trifluoro-p-tolyl)oxy]-propylamine)] a selective serotonin reuptake inhibitor, is widely used in treating depression and other serotonin-dependent disease conditions. Racemic, (R)- and (S)-fluoxetine are potent reversible inhibitors of CYP2D6, and the racemate has been shown to be a mechanism-based inhibitor of CYP3A4. Racemic fluoxetine also demonstrates time- and concentration-dependent inhibition of CYP2C19 catalytic activity in vitro. In this study, we compared fluoxetine, its (R)- and (S)-enantiomers, ticlopidine, and S-benzylnirvanol as potential time-dependent inhibitors of human liver microsomal CYP2C19. In a reversible inhibition protocol (30 min preincubation with liver microsomes without NADPH), we found (R)-, (S)- and racemic fluoxetine to be moderate inhibitors with IC₅₀ values of 21, 93, and 27 µM, respectively. However, when the preincubation was supplemented with NADPH, IC₅₀ values shifted to 4.0, 3.4, and 3.0 µM, respectively resulting in IC₅₀ shifts of 5.2-, 28-, and 9.3-fold. Ticlopidine showed a 1.8-fold shift in IC₅₀ value, and S-benzylnirvanol shifted right (0.41-fold shift). Follow-up K_I and k_inact determinations with fluoxetine confirmed time-dependent inhibition [K_I values of 6.5, 47, and 14 µM; k_inact values of 0.023, 0.085, 0.030 min^–1 for (R)-, (S)-, and racemate, respectively]. Although the (S)-isomer exhibits a much lower affinity for CYP2C19 inactivation relative to the (R)-enantiomer, it exhibits a more rapid rate of inactivation. Racemic norfluoxetine exhibited an 11-fold shift (18–1.5 µM) in IC₅₀ value, suggesting that conversion of fluoxetine to this metabolite represents a metabolic pathway leading to time-dependent inhibition. These data provide an improved understanding of the drug-interaction potential of fluoxetine.